• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续多巴胺能刺激:它是左旋多巴运动并发症的答案吗?

Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?

作者信息

Nutt John G

机构信息

Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon 97239-3098, USA.

出版信息

Mov Disord. 2007 Jan;22(1):1-9. doi: 10.1002/mds.21060.

DOI:10.1002/mds.21060
PMID:16958130
Abstract

Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long-term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized.

摘要

持续多巴胺能刺激(CDS)是一种治疗策略,其假设通过预防或逆转脉冲式多巴胺能刺激所诱导的敏化作用,来避免或减少长期左旋多巴治疗的运动并发症、运动波动及异动症。CDS假说本身基于若干假说。其一,持续性多巴胺能刺激是生理性的。其二,敏化作用是不良的,应予以逆转。其三,可同时诱导关期时间及异动症的减少。最后,临床研究证实了CDS假说。本文对这些假说的证据进行了综述,并强调了开展严格检验CDS假说的随机临床试验的必要性。

相似文献

1
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?持续多巴胺能刺激:它是左旋多巴运动并发症的答案吗?
Mov Disord. 2007 Jan;22(1):1-9. doi: 10.1002/mds.21060.
2
Preventing levodopa-induced dyskinesias.预防左旋多巴诱发的运动障碍。
Ann Neurol. 2000 Apr;47(4 Suppl 1):S167-76; discussion S176-8.
3
The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.帕金森病治疗中运动并发症的发生及持续多巴胺能刺激的假说
Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S9-S15. doi: 10.1016/S1353-8020(09)70005-7.
4
The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease.帕金森病治疗中连续多巴胺能刺激的治疗理念。
Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S68-71. doi: 10.1016/S1353-8020(09)70784-9.
5
Clinical pharmacology of levodopa-induced dyskinesia.左旋多巴诱发异动症的临床药理学
Ann Neurol. 2000 Apr;47(4 Suppl 1):S160-4; discussion S164-6.
6
Medical treatment of levodopa-induced dyskinesias.左旋多巴诱导的运动障碍的医学治疗。
Ann Neurol. 2000 Apr;47(4 Suppl 1):S179-88.
7
Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.药物洞察:帕金森病治疗中的持续多巴胺能刺激
Nat Clin Pract Neurol. 2006 Jul;2(7):382-92. doi: 10.1038/ncpneuro0222.
8
A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.帕金森病中左旋多巴或多巴胺激动剂诱发异动症的病理生理机制假说:对未来治疗策略的启示
Mov Disord. 1990;5(2):100-8. doi: 10.1002/mds.870050203.
9
The spectrum of levodopa-induced dyskinesias.左旋多巴诱发的运动障碍的频谱
Ann Neurol. 2000 Apr;47(4 Suppl 1):S2-9; discussion S9-11.
10
[Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].左旋多巴/卡比多巴肠凝胶在晚期帕金森病中的应用
Neuropsychopharmacol Hung. 2015 Dec;17(4):191-6.

引用本文的文献

1
Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease.非侵入式、连续口服给予左旋多巴-卡比多巴固体剂治疗帕金森病。
Sci Rep. 2024 Nov 5;14(1):26826. doi: 10.1038/s41598-024-78145-4.
2
An Individualized Multi-Modal Approach for Detection of Medication "Off" Episodes in Parkinson's Disease via Wearable Sensors.一种通过可穿戴传感器检测帕金森病药物“失效”发作的个性化多模态方法。
J Pers Med. 2023 Jan 31;13(2):265. doi: 10.3390/jpm13020265.
3
Update on the Management of Parkinson's Disease for General Neurologists.
普通神经科医生帕金森病管理的最新进展
Parkinsons Dis. 2020 Mar 26;2020:9131474. doi: 10.1155/2020/9131474. eCollection 2020.
4
Dyskinesia in multiple system atrophy and progressive supranuclear palsy.多系统萎缩和进行性核上性麻痹中的运动障碍。
J Neural Transm (Vienna). 2019 Jul;126(7):925-932. doi: 10.1007/s00702-019-02012-0. Epub 2019 May 13.
5
Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress.甲基苯丙胺诱导的表观遗传效应和甲基苯丙胺依赖的氧化应激。
Oxid Med Cell Longev. 2018 Jul 22;2018:4982453. doi: 10.1155/2018/4982453. eCollection 2018.
6
Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.基于自组装纳米胶束系统的左旋多巴连续透皮给药
Pharm Res. 2017 Jul;34(7):1459-1468. doi: 10.1007/s11095-017-2162-y. Epub 2017 Apr 12.
7
Preparation and evaluation of rotigotine-loaded implant for the treatment of Parkinson's disease and its evolution study.用于治疗帕金森病的罗替戈汀植入剂的制备与评价及其演变研究。
Saudi Pharm J. 2016 May;24(3):363-70. doi: 10.1016/j.jsps.2016.04.022. Epub 2016 May 5.
8
Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.药物治疗对帕金森病患者生活质量的影响
CNS Drugs. 2015 May;29(5):397-413. doi: 10.1007/s40263-015-0247-x.
9
Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.治疗帕金森病患者左旋多巴诱导运动障碍的药物策略。
CNS Drugs. 2014 Dec;28(12):1155-84. doi: 10.1007/s40263-014-0205-z.
10
Parkinson's disease patients with pain suffer from more severe non-motor symptoms.患有疼痛的帕金森病患者会遭受更严重的非运动症状。
Neurol Sci. 2015 Feb;36(2):263-8. doi: 10.1007/s10072-014-1942-y. Epub 2014 Sep 6.